4 recruiting, 1 not yet recruiting. 5 Phase 2, 4 Phase 1, 1 Phase 3.
By phase and status
Follow Etentamig: new trials by email Literature Review of Etentamig trials Research Report on Etentamig
Trials (filtered) newest first · largest first
All 5 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma Etentamig, Isatuximab, Bortezomib + Lenalidomide + Dexamethasone - Myeloma Multiple, Myeloma Phase 1 / Phase 2 Not yet recruiting 220 2026-12-01 2026-05-20 ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia Phase 1 / Phase 2 Recruiting 38 2026-09-30 2026-10-05 A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant Etentamig, Lenalidomide, Daratumumab - Multiple Myeloma Phase 2 / Phase 3 Recruiting 680 2026-01-08 2026-10-19 A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) Surzetoclax, Daratumumab, Dexamethasone - Multiple Myeloma Phase 1 / Phase 2 Recruiting 325 2025-07-23 2026-10-27 A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations Etentamig, Lenalidomide, Dexamethasone - Multiple Myeloma Phase 1 / Phase 2 Recruiting 602 2025-06-30 2026-10-19
Conditions studied Multiple Myeloma (4) · Neoplasms (2) · Neoplasms, Plasma Cell (1) · Waldenstrom Macroglobulinemia (1)
Sponsors AbbVie (3) · Mayo Clinic (1) · Universitätsklinikum Hamburg-Eppendorf (1)
Countries United States (4) · Japan (3) · Australia (2) · France (2) · Germany (2) · Israel (2) · United Kingdom (2) · Belgium (1) · Italy (1) · Norway (1) · Poland (1) · Portugal (1) · Spain (1) · Sweden (1)
Top investigators Prashant Kapoor, MD (1)
NIH funding 2025 (2)